Fremanezumab parenteral
- Drugs List
- Therapeutic Indications
- Dosage
- Administration
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Injections of fremanezumab.
Drugs List
Therapeutic Indications
Uses
Migraine in adults: prophylaxis
Prophylaxis of migraine in adults who have at least 4 migraine days per month.
Dosage
Adults
225mg once monthly.
Alternatively 675mg every three months.
When switching dosing regimens, the first dose of the new regimen should be administered on the next scheduled dosing date of the prior regimen.
Concomitant migraine preventive treatment may be continued if necessary.
Additional Dosage Information
A missed dose should be resumed as soon as possible at the indicated dose and regimen. A double dose should not be administered.
Administration
Fremanezumab is for subcutaneous injection only.
Contraindications
Children under 18 years
Pregnancy
Precautions and Warnings
Patients over 65 years
Breastfeeding
Severe cardiovascular disorder
Severe renal impairment
Treatment to be initiated by specialist
Do not use if contents have been frozen
Record name and batch number of administered product
Assess benefit within 3 months and evaluate continued need regularly
Discontinue if hypersensitivity reactions occur
Discontinue if serious allergic or anaphylactic reaction occurs
Hypersensitivity reactions have been reported with the use of fremanezumab within hours to one month after administration.
Pregnancy and Lactation
Pregnancy
Fremanezumab is contraindicated during pregnancy.
The manufacturer recommends avoiding fremanezumab during pregnancy.
At the time of writing there is limited data available regarding fremanezumab in pregnancy, animal studies do not indicate harmful effects with respect to reproductive toxicity.
Lactation
Use fremanezumab with caution during breastfeeding.
The manufacturer advises caution if fremanezumab is used when breastfeeding. The presence of fremanezumab in human breast milk is unknown. However, human IgG is excreted in breast milk during the first days after birth, which is decreasing to low concentrations soon afterwards, consequently, a risk to the infant cannot be excluded during this short period. Afterwards, fremanezumab could be considered during breastfeeding only if clinically needed. Effects on breastfed infants are unknown.
LactMed (2020) indicates that since fremanezumab is a large protein molecule with a molecular weight of about 148,000, the amount in breast milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract.
Side Effects
Anaphylactic reaction
Erythema at injection site
Hypersensitivity reactions
Induration (injection site)
Itching (injection site)
Local pain (injection site)
Pruritus
Rash
Rash at injection site
Swelling
Urticaria
Further Information
Last Full Review Date: November 2021
Reference Sources
Summary of Product Characteristics: Ajovy 225mg pre-filled syringe for injection. Teva UK Ltd. Revised February 2022.
Summary of Product Characteristics: Ajovy 225mg pre-filled pen for injection. Teva UK Ltd. Revised February 2022.
US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
Available at: https://www.ncbi.nlm.nih.gov/books/NBK501922/
Fremanezumab. Last revised: 20 July 2020.
Last accessed: 20 December 2021.
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.